Filtered By:
Condition: Heart Failure
Therapy: Statin Therapy
This page shows you your search results in order of relevance. This is page number 20.
Order by Relevance | Date
Total 331 results found since Jan 2013.
Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey)
CONCLUSIONS: Among patients receiving statins, cardiovascular event incidence did not differ significantly between O3AEE-treated patients and non-O3AEE-treated patients. Further studies are required before definitive conclusions can be drawn on the effect of O3AEE on cardiovascular event incidence in high-risk patients with hypertriglyceridemia.TRIAL REGISTRATION: ClinicalTrials.gov, NCT02285166.PMID:35772177 | DOI:10.1080/14740338.2022.2094914
Source: Expert Opinion on Drug Safety - June 30, 2022 Category: Drugs & Pharmacology Authors: Tamio Teramoto Hisao Ogawa Hirotsugu Ueshima Yasushi Okada Kazuo Haze Shigeyuki Matsui Keita Fujikawa Takamasa Hashimoto Sho Sakui Kunihiko Nishimura Mika Kajita Atsushi Horimoto Jovelle Fernandez Source Type: research
Cardiodiabetology: Newer Pharmacologic Strategies for Reducing Cardiovascular Disease Risks
Can J Physiol Pharmacol. 2022 Jun 30. doi: 10.1139/cjpp-2022-0065. Online ahead of print.ABSTRACTGlobally, nearly 500 million adults currently have diabetes, which is expected to increase to approximately 700 million by 2040. Cardiovascular diseases (CVD), including coronary heart disease, stroke, heart failure, and peripheral arterial disease, are the principal causes of death in persons with diabetes. Key to the prevention of CVD is optimization of associated risk factors. However, few persons with diabetes are at recommended targets for key CVD risk factors including LDL-cholesterol, blood pressure, HbA1c, nonsmoking st...
Source: Canadian Journal of Physiology and Pharmacology - June 30, 2022 Category: Drugs & Pharmacology Authors: Nathan D Wong Source Type: research
Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey)
CONCLUSIONS: Among patients receiving statins, cardiovascular event incidence did not differ significantly between O3AEE-treated patients and non-O3AEE-treated patients. Further studies are required before definitive conclusions can be drawn on the effect of O3AEE on cardiovascular event incidence in high-risk patients with hypertriglyceridemia.TRIAL REGISTRATION: ClinicalTrials.gov, NCT02285166.PMID:35772177 | DOI:10.1080/14740338.2022.2094914
Source: Expert Opinion on Drug Safety - June 30, 2022 Category: Drugs & Pharmacology Authors: Tamio Teramoto Hisao Ogawa Hirotsugu Ueshima Yasushi Okada Kazuo Haze Shigeyuki Matsui Keita Fujikawa Takamasa Hashimoto Sho Sakui Kunihiko Nishimura Mika Kajita Atsushi Horimoto Jovelle Fernandez Source Type: research
Cardiodiabetology: Newer Pharmacologic Strategies for Reducing Cardiovascular Disease Risks
Can J Physiol Pharmacol. 2022 Jun 30. doi: 10.1139/cjpp-2022-0065. Online ahead of print.ABSTRACTGlobally, nearly 500 million adults currently have diabetes, which is expected to increase to approximately 700 million by 2040. Cardiovascular diseases (CVD), including coronary heart disease, stroke, heart failure, and peripheral arterial disease, are the principal causes of death in persons with diabetes. Key to the prevention of CVD is optimization of associated risk factors. However, few persons with diabetes are at recommended targets for key CVD risk factors including LDL-cholesterol, blood pressure, HbA1c, nonsmoking st...
Source: Canadian Journal of Physiology and Pharmacology - June 30, 2022 Category: Drugs & Pharmacology Authors: Nathan D Wong Source Type: research
Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey)
CONCLUSIONS: Among patients receiving statins, cardiovascular event incidence did not differ significantly between O3AEE-treated patients and non-O3AEE-treated patients. Further studies are required before definitive conclusions can be drawn on the effect of O3AEE on cardiovascular event incidence in high-risk patients with hypertriglyceridemia.TRIAL REGISTRATION: ClinicalTrials.gov, NCT02285166.PMID:35772177 | DOI:10.1080/14740338.2022.2094914
Source: Expert Opinion on Drug Safety - June 30, 2022 Category: Drugs & Pharmacology Authors: Tamio Teramoto Hisao Ogawa Hirotsugu Ueshima Yasushi Okada Kazuo Haze Shigeyuki Matsui Keita Fujikawa Takamasa Hashimoto Sho Sakui Kunihiko Nishimura Mika Kajita Atsushi Horimoto Jovelle Fernandez Source Type: research
Cardiodiabetology: Newer Pharmacologic Strategies for Reducing Cardiovascular Disease Risks
Can J Physiol Pharmacol. 2022 Jun 30. doi: 10.1139/cjpp-2022-0065. Online ahead of print.ABSTRACTGlobally, nearly 500 million adults currently have diabetes, which is expected to increase to approximately 700 million by 2040. Cardiovascular diseases (CVD), including coronary heart disease, stroke, heart failure, and peripheral arterial disease, are the principal causes of death in persons with diabetes. Key to the prevention of CVD is optimization of associated risk factors. However, few persons with diabetes are at recommended targets for key CVD risk factors including LDL-cholesterol, blood pressure, HbA1c, nonsmoking st...
Source: Canadian Journal of Physiology and Pharmacology - June 30, 2022 Category: Drugs & Pharmacology Authors: Nathan D Wong Source Type: research
Serum cholesterol loading capacity on macrophages is linked to coronary atherosclerosis and cardiovascular event risk in rheumatoid arthritis
CONCLUSION: CLC was linked to long-term cardiovascular event risk in RA and associated with high-risk low attenuation and obstructive coronary plaque presence and burden in bDMARD non-users. Its prospective validation as a predictive biomarker may be, therefore, warranted.PMID:36113961 | DOI:10.1136/rmdopen-2022-002411
Source: Atherosclerosis - September 16, 2022 Category: Cardiology Authors: George Athanasios Karpouzas Bianca Papotti Sarah Ormseth Marcella Palumbo Elizabeth Hernandez Maria Pia Adorni Francesca Zimetti Matthew Budoff Nicoletta Ronda Source Type: research
Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: Results from a global meta-analysis of 1,285,722 patients
CONCLUSION: In this study level meta-analysis, SMuRF-less ACS patients demonstrate higher mortality compared with patients with at least one traditional atherosclerotic risk factor. Underuse of guideline-directed medical therapy amongst SMuRF-less patients is concerning. Unraveling novel risk factors amongst SMuRF-less individuals is the next important step.SUMMARY: Standard modifiable cardiovascular risk factors (SMuRF), comprising diabetes mellitus, hyperlipidemia, hypertension, and smoking, are often used for risk stratification in acute coronary syndrome (ACS). Recent studies showed an increasing proportion of SMuRF-le...
Source: Atherosclerosis - September 30, 2022 Category: Cardiology Authors: Gwyneth Kong Yip Han Chin Bryan Chong Rachel Sze Jen Goh Oliver Zi Hern Lim Cheng Han Ng Mark Muthiah Roger Foo Stephen T Vernon Poay Huan Loh Mark Y Chan Nicholas W S Chew Gemma A Figtree Source Type: research
Prognostic Implication of Small Dense LDL-Cholesterol Levels following Acute Coronary Syndrome
Conclusions: Small dense LDL-cholesterol level was a significant risk factor for cardiovascular events following presentations of acute coronary syndrome.PMID:36676782 | DOI:10.3390/medicina59010158
Source: Atherosclerosis - January 21, 2023 Category: Cardiology Authors: Teruhiko Imamura Masakazu Hori Nikhil Narang Hiroshi Ueno Koichiro Kinugawa Source Type: research
